Browse studies

Find your next paid study

26 recruiting studies matching your filters

Newest first Highest paying

Phase 1

A Phase 1/2, First-in-Human, Multi-Arm, Dose-Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK), and Efficacy of VV-14303, an Adeno-associated Virus Vector-mediated Fibroblast Growth Factor 21 (FGF21) Gene Therapy, in Adults With Metabolic Dysfunction-associated Steatohepatitis (MASH)

A Study of VV-14303 for the Treatment of Metabolic dysfunction-associated steatohepatitis (MASH)

Metabolic Dysfunction-associated Steatohepatitis (MASH)

Estimated

~$150 – $4,200

Actual pay is set by the research site.

Kriya Therapeutics, Inc.NCT07732400

A Phase 4, Decentralized Observational Registry to Evaluate the Safety in Women With NASH and Their Infants Exposed to REZDIFFRA™ (Resmetirom) During Pregnancy and/or Lactation

To evaluate pregnancy and clinical outcomes in women with NASH and their infants after exposure to Rezdiffra at any time during pregnancy and/or lactation.

MASH - Metabolic Dysfunction-Associated Steatohepatitis

Estimated

~$10 – $1,050

Actual pay is set by the research site.

Madrigal Pharmaceuticals, Inc.NCT07541469

Phase 2

Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate MGL-3196 (Resmetirom) in Patients With MASH Who Have Undergone Liver Transplant for MASH Cirrhosis or Other Etiologies

A Phase 2 double-blind, randomized, placebo-controlled study to evaluate resmetirom in 2 cohorts of subjects with moderate to advanced fibrosis, consistent wit…

MASH - Metabolic Dysfunction-Associated Steatohepatitis

Estimated

~$75 – $2,800

Actual pay is set by the research site.

Madrigal Pharmaceuticals, Inc.NCT07335601

Phase 4

A Prospective Multicenter International Randomized Controlled Trial Comparing Surgical and Medical Therapies in the Treatment of Advanced Metabolic Dysfunction Associated Steatohepatitis

Metabolic dysfunction-associated steatotic liver disease (MASLD), formerly known as non-alcoholic fatty liver disease (NAFLD), a major global public health con…

Metabolic Dysfunction-associated Steatotic Liver Disease (MASLD)Non-Alcoholic Fatty Liver DiseaseMetabolic Dysfunction-Associated Steatohepatitis (MASH)+2 more

Estimated

~$25 – $1,000

Actual pay is set by the research site.

The Cleveland ClinicNCT06374875

Phase 2

A Phase 2a, Multicenter, Open-label, Multiple Ascending Dose Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of Resmetirom in Pediatric Subjects Ages 6-17 Years With MASH With Fibrosis Stage F1-F3

This study will evaluate the safety, pharmacokinetics (how the body absorbs, distributes, metabolizes, and eliminates the drug), and pharmacodynamics (how the …

MASHMASH - Metabolic Dysfunction-Associated Steatohepatitis

Estimated

~$75 – $2,800

Actual pay is set by the research site.

Madrigal Pharmaceuticals, Inc.NCT07763015

Phase 4

A Phase 4, Open-label, Multi-group Study of Rezdiffra® in Combination With Concomitant Therapies Commonly Used to Treat Comorbidities in Adults With MASH and Moderate to Advanced (F2-F3) Fibrosis, Administered According to Their Approved Labeling

To determine the safety of Rezdiffra (Resmetirom) when administered alongside common prescriptions for Diabetes Metellus (Farxiga/dapagliflozin \& Actos/piogli…

MASH - Metabolic Dysfunction-Associated Steatohepatitis

Estimated

~$25 – $1,400

Actual pay is set by the research site.

Madrigal Pharmaceuticals, Inc.NCT07848191

Phase 2

Clinical Trial of Oral Digoxin In NASH (CODIN)

Nonalcoholic steatohepatitis (NASH) is a severe subtype of nonalcoholic fatty liver disease (NAFLD) which affects 1 in 3 Americans. The mainstay of treatment f…

NASHNAFLDMASH - Metabolic Dysfunction-Associated Steatohepatitis+5 more

Estimated

~$75 – $2,000

Actual pay is set by the research site.

Yale UniversityNCT06588699

Thermoacoustic Method for Estimating Liver Fat Fraction - Pilot Study I

The goal of this study is to use our Thermoacoustic Enhanced Ultrasound device to measure the fat levels in your liver and compare it to the the gold standard …

MASLD/MASH (Metabolic Dysfunction-Associated Steatotic Liver Disease / Metabolic Dysfunction-Associated Steatohepatitis)Fatty Liver Disease, Nonalcoholic

Estimated

~$10 – $1,125

Actual pay is set by the research site.

Endra LifesciencesNCT07321925

Observational

Effect of Endoscopic Sleeve Gastroplasty on Patients With Obesity and Concomitant Metabolic Dysfunction-Associated Steatohepatitis (MASH): A Multicenter, Open-label, Randomized Controlled Trial

Metabolic dysfunction-associated steatotic liver disease (MASLD) is the most common chronic liver disease globally. While weight loss through lifestyle modific…

ObesityLiver DiseasesLiver Fibrosis+16 more

Estimated

~$10 – $1,125

Actual pay is set by the research site.

Observational

Randomized Feasibility Trial of Isocaloric Navy-Bean Substitution in Adults With MASLD (Metabolic Dysfunction-Associated Steatotic Liver Disease)

This study is a 24-week randomized crossover feasibility trial evaluating an isocaloric navy-bean dietary substitution in 40 adults with metabolic dysfunction-…

Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)Liver FibrosisMetabolic Dysfunction-Associated Steatohepatitis (MASH)

Estimated

~$10 – $750

Actual pay is set by the research site.

Icahn School of Medicine at Mount SinaiNCT07730853

Phase 3

A Phase 3, Double-blind, Randomized, Placebo Controlled, 2-arm Study to Investigate the Safety and Efficacy of Efimosfermin Alfa Injection in Adult Participants With Compensated Cirrhosis Due to Metabolic Dysfunction-associated Steatohepatitis (NEBULA-1)

This study will investigate the safety and efficacy of efimosfermin alfa in participants with compensated cirrhosis due to MASH.

Metabolic Dysfunction-associated Steatohepatitis

Estimated

~$50 – $2,250

Actual pay is set by the research site.

GlaxoSmithKlineNCT07701993

Phase 1

A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Two-Part Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of a Single Dose of ALN-CIDEB in Adult Participants With Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) and Two Doses of ALN-CIDEB in Adult Participants With Metabolic Dysfunction-Associated Steatohepatitis (MASH)

This study is researching an experimental drug called ALN-CIDEB, also referred to as "study drug". The study is focused on participants with metabolic dysfunct…

Metabolic Dysfunction-Associated Steatotic Liver DiseaseMetabolic Dysfunction-Associated Steatohepatitis

Estimated

~$150 – $4,200

Actual pay is set by the research site.

Regeneron PharmaceuticalsNCT06836609